Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:42 PM
Ignite Modification Date:
2025-12-24 @ 1:42 PM
NCT ID:
NCT02984995
Eligibility Criteria:
Inclusion Criteria:
* AML patients in first relapse or refractory after all prior therapy
* Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2
Exclusion Criteria:
* Diagnosis of acute promyelocytic leukemia
* AML secondary to prior chemotherapy for other neoplasms.
* Persistent, clinically significant \> Grade 1 non-hematologic toxicity from prior AML therapy
* Prior treatment with a FLT3 targeted therapy
* Active infection not well controlled by antibacterial, antifungal and/or antiviral therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Study:
NCT02984995
Study Brief:
Protocol Section:
NCT02984995